CVSA earnings analysis
What we found in CVSA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Covista Inc. recorded a Q3 fiscal 2026 revenue of $487.0 million, exceeding estimates, but reported lower EPS of $1.20, underperforming against expectations. The company raised its fiscal year revenue guidance to $1,930 - $1,945 million and adjusted EPS guidance to $7.95 - $8.15, reflecting strong demand despite segment challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth vs. Prior Periods
- Revenue increased 4.5% or $21.0 million to $487.0 million in Q3 FY2026 compared to the prior year.
- EPS Guidance Raised
- Management increased EPS guidance to $7.95 - $8.15 from $7.80 - $8.00.
- Segment Growth in Medical and Veterinary
- Medical and Veterinary segment grew 8.9% or $8.4 million to $103.5 million in Q3 FY2026.
- Improved Adjusted Earnings
- Adjusted EPS rose 3.1% to $1.98, showcasing effective share repurchases.
- Enrollment Increase at Walden
- Walden's enrollment rose by 12.3% year-over-year, reflecting strong demand.
- Cash Flow from Operations Up
- Net cash from operating activities increased by $72.6 million to $346.4 million for the nine months ending March 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Net Income Decline
- Net income decreased 31.6% to $41.6 million compared to the prior year.
- Operating Margin Pressure
- Operating income grew minimally by 0.9% but underperformed due to rising operational costs.
- Revenue Shift Impact
- Walden revenue performance was complicated by a timing shift of $18M, reducing Q3 reported revenue.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.2
- Segment
- Chamberlain: $197M, Walden: $186.6M, Medical and Veterinary: $103.5M
What they said about what is next.
Management has revised revenue and EPS guidance upward due to strong demand.
The filing reads about the same as the one before it.
What came before.
- 10-Q · October 30, 2025
- Adtalem reported strong Q1 FY2026 results: consolidated revenue of $462,288 (in thousands) was up $44,888 (+10.8% YoY) and operating income rose to $85,477 (in thousands) up $15,239 (+21.7% YoY), driving diluted EPS of…
- 10-Q · May 8, 2025
- Adtalem reported solid Q3 fiscal 2025 results with consolidated revenue of $466,055,000 (up $53,397,000, +12.9% YoY), meaningful operating leverage (operating income $90,509,000 vs $61,725,000) and diluted EPS of $1.59…
- 10-Q · January 30, 2025
- Adtalem reported a strong second quarter (quarter ended Dec 31, 2024) with revenue of $447,729 (thousands), up $54,487 or 13.9% year-over-year, driven by growth at Chamberlain and Walden. Operating income expanded to…
- 10-Q · October 29, 2024
- Adtalem reported a strong Q1 FY2025 with revenue of $417,400 (thousands), up $48,555 or 13.2% YoY, driven by increases at Chamberlain and Walden. Operating income rose to $70,238 (thousands) from $28,194 (thousands) a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CVSA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever